FY2018 Earnings Estimate for Sientra Inc (SIEN) Issued By Dougherty & Co

Sientra Inc (NASDAQ:SIEN) – Investment analysts at Dougherty & Co boosted their FY2018 earnings per share (EPS) estimates for Sientra in a note issued to investors on Tuesday, January 8th. Dougherty & Co analyst K. Bauser now expects that the medical instruments supplier will post earnings of ($3.06) per share for the year, up from their previous estimate of ($3.07). Dougherty & Co also issued estimates for Sientra’s Q4 2018 earnings at ($0.69) EPS and FY2019 earnings at ($2.63) EPS.

Several other brokerages have also issued reports on SIEN. Zacks Investment Research raised Sientra from a “sell” rating to a “hold” rating in a report on Saturday, September 15th. BidaskClub lowered Sientra from a “strong-buy” rating to a “buy” rating in a report on Tuesday, September 18th. Finally, Maxim Group raised Sientra from a “hold” rating to a “buy” rating in a report on Wednesday, December 19th. One investment analyst has rated the stock with a sell rating, one has given a hold rating, nine have issued a buy rating and one has given a strong buy rating to the company. The stock currently has an average rating of “Buy” and an average target price of $22.50.

Shares of SIEN stock opened at $14.55 on Thursday. The stock has a market cap of $424.13 million, a price-to-earnings ratio of -5.16 and a beta of 0.16. Sientra has a 1 year low of $8.79 and a 1 year high of $26.79. The company has a debt-to-equity ratio of 0.36, a quick ratio of 2.34 and a current ratio of 2.77.

Sientra (NASDAQ:SIEN) last issued its quarterly earnings data on Tuesday, November 6th. The medical instruments supplier reported ($0.72) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.67) by ($0.05). The firm had revenue of $16.90 million for the quarter, compared to analysts’ expectations of $16.66 million. Sientra had a negative return on equity of 132.84% and a negative net margin of 126.03%. The business’s revenue for the quarter was up 72.4% compared to the same quarter last year. During the same period in the previous year, the business posted ($0.74) EPS.

Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Metropolitan Life Insurance Co. NY purchased a new position in shares of Sientra during the second quarter worth about $160,000. Accredited Investors Inc. purchased a new position in shares of Sientra during the third quarter worth about $200,000. Tarbox Family Office Inc. grew its holdings in shares of Sientra by 595.3% during the third quarter. Tarbox Family Office Inc. now owns 9,734 shares of the medical instruments supplier’s stock worth $232,000 after buying an additional 8,334 shares during the last quarter. MetLife Investment Advisors LLC purchased a new position in shares of Sientra during the second quarter worth about $226,000. Finally, AQR Capital Management LLC grew its holdings in shares of Sientra by 41.5% during the third quarter. AQR Capital Management LLC now owns 19,345 shares of the medical instruments supplier’s stock worth $462,000 after buying an additional 5,675 shares during the last quarter. 87.01% of the stock is currently owned by hedge funds and other institutional investors.

In related news, Director Timothy Haines sold 89,651 shares of the firm’s stock in a transaction dated Tuesday, November 6th. The stock was sold at an average price of $21.56, for a total transaction of $1,932,875.56. Following the transaction, the director now owns 37,662 shares of the company’s stock, valued at $811,992.72. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Company insiders own 31.00% of the company’s stock.

About Sientra

Sientra, Inc, a medical aesthetics company, develops and sells medical aesthetics products to plastic surgeons in the United States. It operates through two segments, Breast Products and miraDry. The company offers silicone gel breast implants for use in breast augmentation and breast reconstruction procedures; breast tissue expanders; and scar management products under the Sientra, AlloX2, Dermaspan, Softspan, and BIOCORNEUM brand names.

Further Reading: Why is Cost of Capital Important?

Earnings History and Estimates for Sientra (NASDAQ:SIEN)

Receive News & Ratings for Sientra Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sientra and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply